CPC A61K 9/288 (2013.01) [A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); C07K 16/241 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01)] | 13 Claims |
1. A composition comprising (i) an active agent selected from the group consisting of antibodies specific to tumor necrosis factor alpha (TNFα) and functional fragments thereof and (ii) an amount of one or more suitable buffer agents and/or acidifiers effective to reduce the luminal pH in the large intestine, wherein said composition is formulated for rectal administration for use in the treatment of an inflammatory bowel disease in a human patient, further wherein administration of said composition results in the local accumulation of said active agent in the gastrointestinal wall and a decrease of a pH in the large intestinal lumen of said patient to between 5.5 and 6.5.
|